The numerous descriptions of regulatory T (T reg) cells in both animal models and, more recently, in humans have revealed a wide diversity of populations and mechanisms of action. Thymically derived CD4 + CD25 + T reg cells play a crucial role in the maintenance of selftolerance and the prevention of autoimmune disease. This "natural" subset expresses the transcription factor Foxp3, which has emerged as an important functional marker of T reg cell activity, supported by the fact that ectopic Foxp3 expression is suffi cient to empower naive T cells with a regulatory function (1) . CD4 + T reg cells can also be generated in the periphery (adaptive), and many studies have identifi ed diff erent subpopulations of CD4 + T cells based on phenotypic and functional properties (2, 3) . Examples include IL-10-secreting Tr1 cells, which can inhibit colitis in mice (4, 5) , and Th3 cells, which play a role in mediating tolerance via the production of TGF-β (6) . TGF-β has also been shown to mediate suppression by CD4 + CD25 + T reg cells in murine models of autoimmunity (7) . In addition, TGF-β can also confer a suppressive phenotype on polyclonally activated naive T cells in vitro, leading to an expansion of FoxP3 + T reg cells (8) (9) (10) .
The manipulation of the peripheral pool of T reg cells has been a particular focus for the treatment of autoimmune diseases and transplantation. Our previous data showing that T reg cells from patients with rheumatoid arthritis (RA) are functionally defective, and that after infl iximab therapy this defect is reversed, have emphasized the potential of biological therapy (11) . An intriguing observation was the increased number of peripheral blood CD4 + CD25 hi T reg cells seen only in RA patients responding to infl iximab. Thus, TNF-α blockade might, as a consequence of the reduced infl ammation, either "recall" T reg cells from previously infl amed joints or lead to the diff erentiation of "new" T reg cells. Here, we demonstrate that infl iximab treatment induced the diff erentiation of a population of T reg cells
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The induction of regulatory T (T reg) cells holds considerable potential as a treatment for autoimmune diseases. We have previously shown that CD4 + CD25 hi T reg cells isolated from patients with active rheumatoid arthritis (RA) have a defect in their ability to suppress proinfl ammatory cytokine production by CD4 + CD25 − T cells. This defect, however, was overcome after anti-tumor necrosis factor (TNF)-antibody (infl iximab) therapy. Here, we demonstrate that infl iximab therapy gives rise to a CD4 + CD25 hi FoxP3 + T reg cell population, which mediates suppression via transforming growth factor (TGF)-and interleukin 10, and lacks CD62L expression, thereby distinguishing this T reg cell subset from natural T reg cells present in healthy individuals and patients with active RA. In vitro, infl iximab induced the differentiation of CD62L − T reg cells from CD4 + CD25 − T cells isolated from active RA patients, a process dependent on TGF-. In spite of the potent suppressor capacity displayed by this CD62L − T reg cell population, the natural CD62L + T reg cells remained defective in infl iximab-treated patients. These results suggest that anti-TNF-therapy in RA patients generates a newly differentiated population of T reg cells, which compensates for the defective natural T reg cells. Therefore, manipulation of a proinfl ammatory environment could represent a therapeutic strategy for the induction of T reg cells and the restoration of tolerance.
expressing Foxp3 and low levels of CD62L through conversion of CD4 + CD25 − T cells.
RESULTS AND DISCUSSION
The expanded population of T reg cells from infl iximabtreated patients is Foxp3 + and CD62L − First, we addressed whether the increased number of CD4 + CD25 hi T cells observed in RA patients responding to infl iximab therapy corresponded to an increase of T reg cells or simply refl ected an increase in the percentage of activated T cells. Peripheral CD4 + T cells isolated from healthy, active RA patients and those treated with infl iximab were analyzed for the expression of the transcription factor Foxp3 by intracellular staining. A two-to threefold increase in the percentage of CD4 + Foxp3 + cells was observed in the PBMCs of postinfl iximab patients compared with active RA patients or healthy individuals, suggesting that the increase in CD25 expression in post-anti-TNF-α-treated patients refl ects increased numbers of T reg cells (Fig. 1 A) . There was no signifi cant diff erence in FoxP3 expression in CD4 + T cells from active RA patients compared with healthy controls. To better characterize the phenotype of the T reg cells after infl iximab, we measured surface markers representative of activation, memory, and regulation. A signifi cant increase in the percentage of CD4 + CD25 hi CD62L − was observed in PMBCs from infl iximab-treated patients compared with RA patients with active disease before infl iximab and healthy individuals (Fig. 1 B) . As previous data has indicated that the 
BRIEF DEFINITIVE REPORT
most potent CD4 + CD25 hi T reg cell subset expressed CD62L (12), we next assayed the expression of CD62L in the CD4 + Foxp3 + population. Although most CD4 + Foxp3 + cells from healthy individuals and patients with active RA expressed CD62L, the profi le of expression was remarkably diff erent after infl iximab treatment, where the majority of CD4 + Foxp3 + cells expressed low levels of CD62L (Fig.  1 C) . There was no change in the percentage of Foxp3 + cells or shift in CD62L expression in patients responding to methotrexate (not depicted). Compared with the T reg cells found in healthy individuals and patients with active disease, RA T reg cells post-infl iximab expressed CD45RO but had a reduced expression of CCR7 (Fig. 1 D) . Further examination of the CD4 + Foxp3 + CD62L − RA T reg cells post-infl iximab revealed that these cells lacked CCR7 expression and remained CD45RO + (Fig. 1 E) .
CD62L − T reg cells from infl iximab-treated RA patients mediate their suppressive action through TGF-and IL-10
We next tested whether the CD4 + CD25 hi CD62L − T reg cells isolated from infl iximab-treated patients were functionally suppressive. CD4 + CD25 hi were FACS sorted according to their expression of CD62L (identifi ed as CD62L + and CD62L − T reg cells; Fig. S1 , available at http://www.jem .org/cgi/content/full/jem.20061531/DC1), and their regulatory capacity was assessed with respect to inhibition of proliferation and TNF-α and IFN-γ production by autologous CD4 + CD25 − T cells. In agreement with previous studies (12), CD62L + T reg cells isolated from healthy individuals were more potent at suppressing CD4 + CD25 − T cell proliferation than CD62L − T reg cells (Fig. 2 A) . Conversely, CD62L − T reg cells isolated from RA patients after infl iximab exhibited a more potent suppression of T cell proliferation than their CD62L + T reg cell counterparts. Similarly, we observed a "switch" in the suppressor population from CD62L + T reg cells in healthy individuals to CD62L − T reg cells in patients after infl iximab, with respect to inhibition of IFN-γ and TNF-α production ( Fig. 2 B) . There was a substantial reduction in the suppressor potency of CD62L + T reg cells isolated from patients with active RA compared with healthy individuals, confi rming that CD4 + CD25 hi T reg cells are defective in RA patients (11) . Of importance, the potency of the CD62L + T reg cells after anti-TNF-α therapy was not restored to levels found in healthy controls (Fig. 2 B) . Collectively, these results raise the intriguing possibility that the natural T reg cells (CD62L + T reg cells) remain defective in patients even after infl iximab therapy, and that the previously reported restoration of function of CD4 + CD25 hi T reg cells after infl iximab therapy could be due to the diff erentiation of a new population of CD62L − T reg cells.
To explore the eff ector mechanisms of the CD62L − T reg cells derived from post-infl iximab RA patients, we examined the cytokine dependency of their suppressive eff ect. T reg cells were cocultured with autologous CD4 + CD25 − T cells in the presence of neutralizing mAbs to TGF-β and IL-10, previously recognized as regulatory cytokines involved in the suppressive mechanism of adaptive T reg cells (2) . The data shown in Fig. 2 C demonstrate that in healthy individuals, the suppressive eff ect of CD62L − T reg cells was unaltered by the neutralization of TGF-β or IL-10. In contrast, the neutralization of TGF-β, and to a lesser extent IL-10, signifi cantly impaired the suppressive capacity of the CD62L − T reg cells from infl iximab-treated patients. When the action of both TGF-β and IL-10 was blocked, the suppressive activity of these CD62L − T reg cells was almost abolished. The potency of CD62L + T reg cells from healthy individuals was unaltered by blockade of IL-10 or TGF-β (not depicted). The results reported here appear at odds with our previous fi ndings showing that suppression required contact between T reg cells isolated from infl iximab patients and their autologous CD4 + CD25 − T cells (11) . However, the two results may not be directly comparable because in the previous work, suppression was assayed without separating the CD62L + and CD62L − T reg cell subsets. Therefore, we assayed the functional properties of purifi ed CD62L − T reg cells isolated from RA patients after infl iximab therapy to dissect out their mode of action. The data shown in Fig. 2 D demonstrate that cell contact is required to eff ect maximal suppression of TNF-α and IFN-γ production by CD4 + CD25 − T cells, although some cytokine suppression is still observed when cell contact is prevented. The fact that the T reg cells isolated from patients after infl iximab required both cell contact and cytokines for their suppressive eff ect could be explained by data indicating that TGF-β can mediate suppression through cell contact, when the predominant form of TGF-β is membrane bound (13) . In addition, in some experimental systems, IL-10 production also depends on cell contact between T reg cells and CD4 + CD25 − T cells (14) . Collectively, these results suggest that infl iximab therapy gives rise to, or recruits from the periphery, a population of T reg cells that phenotypically and functionally diff ers from natural T reg cells present in healthy individuals or in patients with active RA.
In vitro infl iximab stimulation of CD4 + CD25 − T cells from RA patients induced a CD62L − T reg cell population To investigate the possible provenance of CD62L − T reg cells, infl iximab was added in vitro to CD4 + CD25 − T cells isolated from active RA or healthy individuals, and the expression of Foxp3 was measured by intracellular staining. The addition of infl iximab to purifi ed active RA CD4 + CD25 − T cells resulted in a substantial increase in the percentage of CD4 + Foxp3 + cells (Fig. 3 A) , whereas no such eff ect was seen when CD4 + CD25 − T cells were isolated from healthy individuals. Neutralization of TGF-β in this culture system completely prevented the diff erentiation of the CD4 + Foxp3 + T cell population from the CD4 + CD25 − T cells (Fig. 3 A) . Moreover, infl iximab induced a signifi cant increase in TGF-β production from CD4 + CD25 − T cells from patients with active RA, but not healthy individuals (Fig. 3 B) . To determine whether infl iximab modulates natural T reg cell Foxp3 expression, CD4 + CD25 hi T cells were isolated from healthy individuals or patients with active RA and cultured with infl iximab. The results in Fig. 3 C show that infl iximab 
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did not aff ect the expression of FoxP3 on CD4 + CD25 hi T reg cells, supporting the evidence that this agent targets CD4 + CD25 − T cells rather than modulating preexisting T reg cells. We next measured CD62L expression after culture of CD4 + CD25 − T cells with infl iximab. The addition of infl iximab to CD4 + CD25 − T cells from active RA patients, but not from healthy individuals, led to a reduction in CD62L expression (Fig. 3 D) . Thus, these in vitro infl iximab-generated T cells share reduced CD62L expression as a common feature with the T reg cells present in the PBMCs of RA patients that had received infl iximab therapy.
We sought to confi rm that the Foxp3 + T cells diff erentiated upon infl iximab stimulation possess suppressor activity. Because the majority of purifi ed CD4 + CD25 − T cells had acquired CD25 expression when stimulated with anti-CD3/ CD28, with or without infl iximab, the CD4 + CD25 + T cells were purifi ed and cultured with freshly isolated autolo gous CD4 + CD25 − T cells. Only the CD4 + CD25 + T cells de rived from active RA patients, but not healthy individuals, which had been cocultured with infl iximab, were able to suppress production of IFN-γ and TNF-α from freshly isolated CD4 + CD25 − T cells (Fig. 3 E) .
The potential of T reg cells to modulate immune responses has led to considerable interest in their use for the treatment of autoimmune disease. Two broad therapeutic approaches have been considered; fi rst, to expand T reg cells in vitro with the intention of infusing these cells into patients, and second, to manipulate the immune system in vivo resulting in an increase in T reg cells. Infl iximab, a monoclonal anti-TNF-α antibody, appears to be an example of the latter and demonstrates that inhibition of a proinfl ammatory cytokine can result in an expanded T reg cell population. Infl iximab led to the diff erentiation of a population of T reg cells identifi ed as FoxP3 + CD25 hi CD62L − CCR7 − in patients with RA. These T reg cells are phenotypically distinct from natural T reg cells, which express CD62L and CCR7, but also diff er functionally as their suppressor capacity depends on the production of TGF-β and IL-10. Murine studies have demonstrated the importance of IL-10 and/or TGF-β in providing increased regulatory potency to CD4 + CD25 + T reg cells in the face of an infl ammatory response (7, 15, 16) or in the prevention of graft rejection (17) . In addition, IL-10-mediated suppression is used by CD4 + CD25 hi HLA-DR − T reg cells found in healthy individuals (18) . Of relevance to this work, CD4 + CD25 + CD62L − T reg cells, producing both IL-10 and TGF-β, have been identifi ed in diabetic mice treated with a combination of anti-CD3 and insulin (19) . In patients with diabetes, anti-CD3 therapy expanded a population of CD4 + CD25 + CD62L − T cells (20) . Thus, anti-CD3 treatment in the context of diabetes and anti-TNF-α therapy for RA both induce a population of T reg cells with a memory phenotype (CCR7 − CD62L − ) (21), perhaps suggesting a similar provenance.
The T reg cells found in post-infl iximab RA patients may have arisen either from CD4 + CD25 − T cells that had already begun to diff erentiate along a Foxp3 + pathway in vivo, or from CD4 + CD25 − responder T cells. The purifi ed CD4 + CD25 − T cells still contain a small fraction of Foxp3 + cells, which could be targeted by infl iximab. CD127, which negatively correlates with Foxp3 expression, could be used to further exclude Foxp3 + cells in the CD4 + CD25 − T cells (22) . However, TGF-β appeared to mediate the infl iximabdriven increase in Foxp3 + T reg cells, which is known to target CD4 + CD25 − T cells rather than natural T reg cells (8) (9) (10) . Moreover, the data shown in Fig. 3 C demonstrate that infl iximab has no eff ect on CD4 + CD25 hi Foxp3 + T cells. Recent fi ndings have revealed that TGF-β can also have a proinfl ammatory role dependent on the immunological environment (23) . Thus, in the presence of proinfl ammatory cytokines, TGF-β contributes to the generation of immunopathogenic IL-17-secreting T cells (24) (25) (26) . Consequently, the prerequisite for the generation of T reg cells, rather than IL-17-secreting T cells, by TGF-β is the removal of proinfl ammatory cytokines, specifi cally IL-6, but also TNF-α and IL-1. Infl iximab can serve this function well as it is known to rapidly reduce levels of IL-6 (27), the critical partner for TGF-β in the production IL-17-producing T cells.
Although Foxp3 expression has been clearly linked to T reg cell activity in murine studies, this association has been less well established in humans. This is particularly true in the context of in vitro activation studies where transient expression of Foxp3 can occur (28) . The ability of infl iximab to confer a suppressive capacity on CD4 + CD25 − T cells could be explained by the presence of activated T cells producing the immunoregulatory cytokines IL-10 and TGF-β. These T reg cells could be similar to activated Tr1 or Th3 cells identifi ed by others (4) (5) (6) .
We have previously shown that CD4 + CD25 hi T reg cell function in RA patients was defective and that this defect was reversed after infl iximab treatment (11) . However, the data presented here lead to an important reinterpretation of our previous fi nding, specifi cally that the naturally derived T reg cells, defi ned as CD4 + CD25 hi CD62L + , appear to remain defective after treatment with anti-TNF-α therapy. The restoration of function of the CD4 + CD25 hi population after infl iximab therapy is most likely to be due to the suppressive eff ects of the newly diff erentiated CD62L − T reg cells. In patients with RA receiving infl iximab, the diff erentiation of adaptive T reg cells could be further amplifi ed by their ability to confer a further suppressive activity on CD4 + CD25 − T cells (29) . One could envisage a feedback mechanism in which infl iximab drives the production of TGF-β by T cells, which would then induce their diff erentiation into FoxP3 + CD62L − T reg cells. Why natural T reg cells remain defective after the neutralization of the proinfl ammatory environment by infl iximab is unclear. It is possible that the reversal of the proinfl ammatory milieu by TNF-α blockade may only be partial, suffi cient to allow the generation of T reg cells from CD4 + CD25 − T cells but insuffi cient to restore function to the natural CD62L + T reg cells. It is tempting to speculate that the induction of T reg cells after infl iximab therapy could lead to restoration of tolerance and might partly explain the exciting observation that infl iximab can induce remission in some patients with early RA after cessation of therapy (30) . In conclusion, our results indicate that T reg cells can be induced, and tolerance restored, by targeting specifi c proinfl ammatory cytokines such as TNF-α.
MATERIALS AND METHODS
Patient population. 31 patients with active RA, fulfi lling the revised classifi cation criteria of the American College of Rheumatology for RA, were evaluated before and 4-6 mo after anti-TNF-α therapy (see reference 11 for infl iximab regime and further details for patient selection and assessment of disease activity, all of which remained the same for this study). 20 healthy individuals were used as controls. This study was approved by the University College London Hospital (UCLH) Ethics Committee.
Antibodies. The following antibodies were used: FITC-anti-CD4 (RPA-T4), PE-Cy5-anti-CD25 (M-A251), PE-anti-CD62L (Dreg-56), PE-CY7-anti-TNF-α (Mab11), PE-Cy7-anti-IFN-γ (45.B3), PE-FoxP3 (PCH-101), APC-anti-CCR7 (3D12), and PE-anti-CD45RO (UCLH1). T cells were activated with soluble anti-CD3 (HIT-3a) and anti-CD28 (CD28.2) as indicated. All antibodies were from BD Biosciences, except FoxP3, which was from eBioscience. For neutralization experiments, anti-TGF-β1 (9016.2) and anti-human IL-10 (25209) were used (R&D Systems). Infl iximab, a chimeric IgG1 anti-TNF-α mAb, was donated by Schering-Plough.
Cell isolation. Human blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque (GE Healthcare) and cultured in RPMI 1640 with 100 U/μg/ml penicillin/streptomycin (Life Technologies) and 10% FCS (Sera Laboratories International, Ltd.). Magnetic bead separation was performed as described previously (11), with all magnetic columns and magnetically labeled beads purchased from Miltenyi Biotec. To purify cells using FACS sorting (MoFlo), cells were stained with the above conjugated antibodies (CD4, CD25, and CD62L). Cells were sorted according to gates as indicated in Fig. S1 .
Flow cytometric analysis and cytokine detection. Cells were surface stained as described previously (11) using the above mentioned conjugated antibodies (CD4, CD25, and CD62L). For intracellular analysis of TNF-α and IFN-γ production, cells were cultured at 2 × 10 5 for 48 h with PMA, ionomycin, and Golgi Plug added in the fi nal 5 h of culture. TGF-β1 was quantifi ed using an ELISA kit (R&D Systems). In some experiments, 24-well transwell plates (Costar) with 0.4-μm membrane supports were used.
Proliferation assays.
In all experiments, T reg cells were cultured at 2 × 10 5 cells/ml, with CD4 + CD25 − T cell numbers adjusted accordingly for ratio experiments. Cells were cultured in 96-well U-bottomed plates (Nunc) for 5 d with [ 3 H]thymidine added in last 18 h of culture. Proliferation was measured using a liquid scintillation counter.
Statistical analysis. Statistical signifi cance was determined using Student's t test, with p-values <0.05 regarded as statistically signifi cant.
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